Financing, Equity Capital Markets

Neoleukin Therapeutics

07/20
|
$76.3 Million
Piper Sandler served as bookrunner for Neoleukin Therapeutics, Inc. on a confidentially marketed follow-on offering
Sub-Type
CMFO
Sector
Healthcare
Sub-Sector
Biopharma

Related Transactions

All Transactions
$42.0 Million
Trinitas
Trinitas Capital Management, LLC
Senior Unsecured Notes Offering
Sole Placement Agent
$103.2 Million
Merchants Bancorp
Merchants Bancorp
Passive Bookrunner
$70.0 Million
CereVasc
Bain
Xontogeny
CereVasc, Inc.
CereVasc, Inc. has received a Series B Financing from Bain Capital Life Sciences and Perceptive Xontogeny Venture Fund (PXV)

Financial Advisor
$225.0 Million
Provident Financial Services, Inc.
Provident Financial Services Inc.
Left Bookrunner
$184.7 Million
Skyward Specialty Insurance
Skyward Specialty Insurance
Passive Bookrunner
$100.0 Million
Context Therapeutics LLC
Context Therapeutics LLC
Sole Placement Agent
$50.0 Million
Legion
Riverwood
Legion Technologies, Inc.
Legion Technologies, Inc. has received a growth investment from Riverwood Capital Management L.P.
Financial Advisor
$201.2 Million
Nurix Inc.
Nurix Inc.
Active Bookrunner
$150.0 Million
Blue Ridge Bankshares
Blue Ridge Bankshares, Inc.
PIPE
Sole Placement Agent
$200.0 Million
Praxis Precision Medicines
Praxis Precision Medicines, Inc.
Confidentially Marketed Follow-On Offering
Active Bookrunner
$100.0 Million
Boundless Bio, Inc.
Boundless Bio, Inc.
Initial Public Offering
Active Bookrunner
$75.0 Million
Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc.
Confidentially Marketed Follow-On Offering
Active Bookrunner
$600.0 Million
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc.
Confidentially Marketed Follow-On Offering
Active Bookrunner
$43.0 Million
CSC
CSC Leasing Company, Inc
Reopened Senior Unsecured Notes
Sole Placement Agent
$50.0 Million
Unicycive
Unicycive Therapeutics
PIPE
Joint Placement Agent
$40.0 Million
Skye Bioscience
Skye Bioscience
PIPE
Sole Placement Agent

© 2024 Piper Sandler Companies. Since 1895. All rights reserved.